A Phase 3 interventional study of Androgen blockade + radiation therapy in Prostate Cancer, sponsored by Université de Sherbrooke. Active, not recruiting at 1 site in Canada. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-01-27.
Sponsored by Université de Sherbrooke · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 713 studies in Prostatic Neoplasms with a site in Canada — 119 open to participants now, 223 under way, 64 of them phase 3. Prostatic Neoplasms · Canada.
Among the 713 studies in Prostatic Neoplasms with a site in Canada, this one is the 122nd largest by enrollment of the 636 interventional ones that give a count, is one of 9 that started in 2000, is one of 176 in phase 3, reaches primary completion later than 74 of the 222 other live ones, and was the 71st registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →119 of the 713 studies in Prostatic Neoplasms with a site in Canada are open now. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 18+ · Men only
University Health Network, Toronto · Sites in Canada
Ages 18+ · Men only
AstraZeneca · Sites in Canada, United States, Austria and 18 more countries
Ages 18+ · Men only
GlaxoSmithKline · Sites in Canada, Australia, Japan and 1 more country
Ages 18+ · Men only
AHS Cancer Control Alberta · Sites in Canada
Ages 18+ · Men only
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years to 80 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
713 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 88 · Phase 2 207 · Phase 3 190 · Phase 4 14
First in 1992; this study’s year is marked. 9 started in 2000.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 630 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 100 across the 636 interventional studies, 130 across the 73 observational. Of the 423 that completed or were terminated, 130 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
225 of 713 have an industry lead sponsor. The 10 most frequent:
Université de Sherbrooke is the lead sponsor of 298 studies on the registry; 67 are open to participants now.
Université de Sherbrooke has 2 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
55 of the studies in Prostatic Neoplasms with a site in Canada that are under way reach primary completion within a year, 13 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05169112Phase 3Ottawa Hospital Research InstituteImpact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy | 2026-11 |
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT02446405Phase 3University of SydneyEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | 2026-12-31 |
| NCT00223171Phase 3Université de SherbrookeDuration of Androgen Blockade Combined with Pelvic Irradiation in Prostate Cancers | 2026-12-31 |
| NCT00223145Phase 3Abdenour NabidStudy on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone | 2026-12-31 |
Add all 55 to your calendar (.ics) → With an account.
Among the 713 studies in Prostatic Neoplasms with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to use as a reference the 36-month duration of hormonal therapy according to the European Organization for Research of the Treatment of Cancer (EORTC protocol 22863) : namely one-month of total androgen blockade followed by a luteinizing hormone releasing hormone (LHRH) agonist, all for three years, combined with pelvic and prostate irradiation; this arm is currently considered to be a standard for high-risk prostate cancers. The proposed study intends to challenge the duration of hormonal therapy and verify whether the five-year outcomes in favour of combined treatment in regard to survival (79% versus 62%) and local control (85% versus 48%) can be transposed for hormonal therapy that is half as long, namely 18 months, with the possibility of hormone salvage therapy in the event of biochemical and/or clinical failure (local, regional, or distant); this applies to both arms. The proposed study will compare survival in the two groups and evaluate in each one the total duration of initial hormonal therapy, followed by initial hormonal therapy combined with salvage hormonal therapy, the duration of salvage hormonal therapy until hormonal therapy resistance, and the side effects of this hormonal therapy, with everything being related to an assessment of the quality of life of these patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To have at least one of the following three risk factors:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Androgen blockade : 36 months of androgen blockade : bicalutamide 50 mg die for one month, goserelin 10.8 mg x 12 Q 3 months + radiation therapy : pelvis 44 grays , prostate 70 grays (2 grays/fraction)
Drug: Androgen blockade + radiation therapy
Androgen blockade 18 months : bicalutamide 50 mg die for one month, goserelin 10.8 mg x 6 Q 3 months + radiation therapy ( pelvis 44 grays , prostate 70 grays ,2 grays/fraction)
Drug: Androgen blockade + radiation therapy
Androgen blockade + radiation therapy
Specific survival
Time frame: 10 years
Overall survival
Time frame: 10 years
Treatment morbidity induced versus quality of life based on duration of hormonal therapy
Time frame: 10 years
Disease-free survival
Time frame: 10 years
Site of tumour relapse
Time frame: 10 years
Interval until first biochemical failure
Time frame: 10 years
Interval until second biochemical failure during salvage androgen suppression (hormone-resistant tumour)
Time frame: 10 years
The record gives a start of Oct 2000, a primary completion of Dec 2026 and a completion of Dec 2027. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.